Nobel Prize in medicine honors optogenetics pioneers

Overview

Updated Oct 8

The 2026 Nobel Prize in Physiology or Medicine went to three scientists who built a way to switch individual nerve cells on and off with light. Karl Deisseroth, Peter Hegemann and Georg Nagel share the 12 million Swedish kronor prize for optogenetics.

The first optogenetic therapy is under FDA review; the agency accepted Nanoscope's Mogenry, a gene therapy for the blinding disease retinitis pigmentosa, in September. A decision is expected in the first half of 2027. A separate New England Journal of Medicine trial helped seven of ten blind patients regain some light sensitivity.

Why it matters

Optogenetics lets researchers prove which brain cells cause which behaviors, opening a path to treating psychiatric and neurological disorders.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

12M SEK

Prize amount

Shared equally among the three laureates.

Laureates

Deisseroth, Hegemann and Nagel.

2005

First breakthrough

Deisseroth published light-controlled nerve cell activation.

90B

Human brain nerve cells

Optogenetics helps identify which cells control specific functions.

H1 2027

FDA decision deadline

For Mogenry, the first optogenetic therapy to reach FDA review.

Voices

Curated perspectives — historical figures and your fellow readers.

People Involved

Karl Deisseroth

Professor of bioengineering and psychiatry, Stanford University; Howard Hughes Medical Institute investigator

2026 Nobel laureate

Peter Hegemann

Professor, Humboldt University of Berlin

2026 Nobel laureate

Georg Nagel

Professor, University of Würzburg

2026 Nobel laureate

Susumu Tonegawa

Professor, Massachusetts Institute of Technology

1987 Nobel laureate; collaborated with Deisseroth on engram research

Anna Wedell

Member, Nobel Assembly at Karolinska Institutet

Presented the 2026 prize

Organizations Involved

Nobel Assembly at Karolinska Institutet

Scientific Committee

Awarded the 2026 prize

The body that awards the Nobel Prize in Physiology or Medicine.

Howard Hughes Medical Institute

Nonprofit medical research organization

Funds Deisseroth's lab

One of the largest private funders of biomedical research in the United States.

Stanford University

University

Deisseroth's home institution

Private research university in California where Deisseroth is a professor.

Timeline

2002 October 2026

8 events Latest: October 5th, 2026 · 1 month ago

Tap a bar to jump to that date

October 2026
Nobel Prize in Physiology or Medicine awarded
Latest Award

Deisseroth, Hegemann and Nagel share the 12 million Swedish kronor prize for optogenetics.
October 5th, 2026
Optogenetic trial shows vision gains in blind patients
Clinical

A New England Journal of Medicine study of 10 people with retinitis pigmentosa found treatment increased light sensitivity in seven participants, six with clinically meaningful improvement.
October 2026
September 2026
FDA accepts first optogenetic therapy for review
Regulatory

The FDA accepted Nanoscope Therapeutics' application for Mogenry, an optogenetic gene therapy for retinitis pigmentosa. A decision is expected in the first half of 2027.
September 2026
2012
Memory engram activated in mice
Breakthrough

Deisseroth and Tonegawa reactivate fear memory nerve cells, causing mice to show fear without danger.
2012
2007
Optogenetics works in living mice
Breakthrough

Deisseroth's group controls whisker movement by illuminating nerve cells in the motor cortex.
2007
2006
Method named optogenetics
Milestone

The technique gets its name, combining 'optic' and 'genetics.'
2006
2005
First light-controlled nerve cell switch
Breakthrough

Deisseroth introduces the channelrhodopsin gene into rat nerve cells and triggers signals with blue light.
2005
2002
Channelrhodopsin discovered in algae
Discovery

Hegemann and Nagel identify a light-gated ion channel in the single-celled alga Chlamydomonas.
2002

Scenarios

Optogenetics restores vision in more patients

Possible Resolves by End of 2028

Discussed by: Nobel Committee member Anna Wedell and the Nobel popular information

Clinical trials aim to restore vision in people blinded by retinitis pigmentosa, a disease that destroys the eye's rods and cones. A patient who received a channelrhodopsin-like protein regained some vision and could grasp objects. If trials expand and succeed, optogenetics becomes the first approved therapy built on this research.

Optogenetics moves into cochlear implants

Possible Resolves by End of 2028

Discussed by: Nobel popular information

Current cochlear implants stimulate the auditory nerve with electricity. Optogenetics could activate the nerve with greater precision. A first human trial would mark the method's second clinical application.

Optogenetics stays a research tool

Likely Resolves by End of 2028

Discussed by: Nobel Committee member Anna Wedell

Most optogenetics work happens in animal models. Wedell said the method is still primarily a basic science tool. Clinical applications beyond vision restoration may take years, and the method's main impact remains in mapping brain circuits.

FDA approves first optogenetic therapy

Possible Resolves by Q2 2027

Discussed by: Nanoscope Therapeutics and the FDA, reported by R&D World

The FDA will decide on Mogenry, an optogenetic gene therapy for retinitis pigmentosa, in the first half of 2027. Approval would make it the first optogenetic medicine to reach the market.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

October 2021

Nobel Prize for temperature and touch receptors (2021)

David Julius and Ardem Patapoutian won the Nobel Prize in Physiology or Medicine for discovering TRP channels and Piezo proteins, the molecular sensors that let the body detect heat, cold and touch.

Then

The prize recognized work on sensory transduction that began in the 1990s.

Now

The discoveries opened new targets for pain and touch disorder treatments.

Why this matters now

Like optogenetics, the work identified specific proteins that convert physical stimuli into nerve signals, showing how molecular discovery can illuminate whole sensory systems.

October 2004

Nobel Prize for olfactory receptors (2004)

Richard Axel and Linda Buck won the Nobel Prize in Physiology or Medicine for discovering the family of receptors that detect odors. Their work showed how a large receptor family encodes a vast range of smells.

Then

The prize recognized the first molecular understanding of smell.

Now

The receptor family became a model for studying how sensory information is encoded in the brain.

Why this matters now

Both prizes recognized molecular discoveries that explained how sensory systems translate external signals into neural activity.